Dhruv Das, Prachi Gupta, Rahul Tambade, P A Hassan, A V S S Narayana Rao, Rajani Kant Chittela
{"title":"Fragment-end sequence architecture of cell-free DNA and its association with tumour DNA in non-small cell lung cancer.","authors":"Dhruv Das, Prachi Gupta, Rahul Tambade, P A Hassan, A V S S Narayana Rao, Rajani Kant Chittela","doi":"10.1002/ctm2.70901","DOIUrl":"10.1002/ctm2.70901","url":null,"abstract":"<p><strong>Introduction: </strong>Circulating cell-free DNA (cfDNA) fragmentation patterns provide a promising source of molecular information for liquid biopsy applications. However, the sequence features underlying fragmentation and their relationship to tumour-derived DNA remain incompletely understood. Here, we characterized fragment-end sequence signatures of extracellular cfDNA across cell lines, extracellular compartments, stress conditions and plasma from patients with non-small cell lung cancer (NSCLC).</p><p><strong>Methods: </strong>cfDNA derived from cell lines was characterized using Oxford Nanopore sequencing, followed by fragment-end analysis. Publicly available Nanopore cfDNA datasets from healthy individuals and NSCLC patients were analyzed to examine dinucleotide patterns and derive a motif ratio index. These signatures were further assessed for their association with estimated ctDNA abundance in an independent cohort of 50 EGFR-mutant NSCLC patients.</p><p><strong>Results: </strong>Nanopore sequencing of A549, H460 and WI38 cell-line cfDNA revealed reproducible end-motif patterns, with enrichment of AT-, GT- and CT-containing termini. Analysis of plasma cfDNA from healthy individuals showed distinct end-motif profiles from cell-line-derived cfDNA, with separation maintained after reducing 4-mer motifs to 5'-terminal dinucleotide features. An exploratory motif ratio based on these patterns showed a modest increase in lung cancer patients compared with healthy individuals. In an independent Illumina cohort of 50 NSCLC patients with activating EGFR mutations, 5'-terminal dinucleotide frequencies were associated with estimated circulating tumour DNA (ctDNA) abundance using cross-validated LASSO (Least Absolute Shrinkage and Selection Operator) regression (Spearman ρ = .73, p = 3.35 × 10<sup>‒9</sup>). The predefined motif ratio showed a strong correlation with estimated ctDNA concentration (Spearman ρ = .76, p = 1.89 × 10<sup>‒10</sup>).</p><p><strong>Conclusion: </strong>These findings suggest that simple, interpretable cfDNA end-motif signatures capture sequence features associated with ctDNA abundance and warrant further validation for non-invasive cancer monitoring.</p>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13770214/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402640","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Ge Zhang, Mingxuan Duan, Tianshu Gu, Qian Guo, Yahui Han, Teng Li
{"title":"What one patient can teach the next.","authors":"Ge Zhang, Mingxuan Duan, Tianshu Gu, Qian Guo, Yahui Han, Teng Li","doi":"10.1002/ctm2.70900","DOIUrl":"10.1002/ctm2.70900","url":null,"abstract":"","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13770209/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402646","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jesenia M. Perez, Justin Hwang, Britt K. Erickson, Stefani N. Thomas
{"title":"Dichotomous assessments of homologous recombination deficiency are insufficient predictive biomarkers for the PARP inhibitor treatment of ovarian cancer","authors":"Jesenia M. Perez, Justin Hwang, Britt K. Erickson, Stefani N. Thomas","doi":"10.1002/ctm2.70890","DOIUrl":"https://doi.org/10.1002/ctm2.70890","url":null,"abstract":"<p>Predictive biomarkers of disease are essential for treatment stratification, prognosticating, and developing strategies to improve outcomes. Assessment of <i>BRCA1/2</i> mutation status and homologous recombination deficiency (HRD) are the current approaches used to designate maintenance treatment for epithelial ovarian cancers (EOC).<span><sup>1</sup></span> The high recurrence rate and poor 5-year survival underscores the importance of comprehensively defining one of the key characteristics of epithelial ovarian cancer: genome instability. With the development of sophisticated multi-omics techniques, the field is well-positioned to expand current dichotomous assessments of HRD to improve the utility of poly (adenosine diphosphate-ribose) polymerase inhibitor (PARPi) therapies in ovarian cancer.</p><p>The primary treatment for advanced-stage ovarian cancer is guided by disease staging from surgery, tumour histotype and primary site, <i>BRCA1/2</i> mutation status, HRD status and patient-related factors such as functional status and comorbidities.<span><sup>2</sup></span> After surgical cytoreduction and completion of primary platinum-based chemotherapy, patients with tumours harbouring <i>BRCA</i> gene variants or HRD can also receive PARPi maintenance therapy (olaparib, niraparib) alone or in combination with the angiogenesis inhibitor, bevacizumab (Table 1).<span><sup>1</sup></span> Patients whose tumours are HRD negative (also known as Homologous Recombination Proficient (HRP)) are given bevacizumab or no further treatment in the maintenance setting.<span><sup>2</sup></span> Despite advancements in the use of neoadjuvant chemotherapy and individualised maintenance therapies with PARPi, disease recurrence is observed in 70% of patients within 3 years of first-line chemotherapy. Additionally, treatment with PARPi frequently leads to the development of haematological toxicities including anaemia, thrombocytopenia, and neutropenia; these adverse events are the main contributors to interruption and discontinuation of PARPi treatment, and they impact patients’ quality of life.<span><sup>3</sup></span> Furthermore, PARPi therapy may increase the risk of fatality due to myelodysplastic syndrome and acute myeloid leukaemia.<span><sup>4</sup></span> The likelihood of the occurrence of these and other adverse events emphasises the importance of appropriate PARPi-treatment stratification in maintenance therapy to reduce disease recurrence, prolong survival, and improve patient quality of life.</p><p>PARPi function by inhibiting single-strand DNA break repair by PARP1 and PARP2 enzymes, leading to the accumulation of mutations and the formation of double-strand DNA breaks.<span><sup>5</sup></span> In tumour cells with non-functional <i>BRCA1/2</i> or HRD, double-strand DNA breaks are repaired through the error-prone non-homologous end joining (NHEJ) pathway, leading to chromosomal instability, cell cycle arrest, and ultimately cell death. This syntheti","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70890","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149310814","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qing Zhu, Nanyan Yang, Xiangzhuo Miao, Shiting Xu, Junming Chen, Huohui Ou, Jianmin Nie, Pengyu Zhu, Yinghao Fang, Dinghua Yang
{"title":"AARS1-mediated PHGDH lactylation promotes hepatocellular carcinoma progression by enhancing serine biosynthesis.","authors":"Qing Zhu, Nanyan Yang, Xiangzhuo Miao, Shiting Xu, Junming Chen, Huohui Ou, Jianmin Nie, Pengyu Zhu, Yinghao Fang, Dinghua Yang","doi":"10.1002/ctm2.70899","DOIUrl":"10.1002/ctm2.70899","url":null,"abstract":"<p><strong>Background: </strong>The recently described lactyltransferase activity of alanyl-tRNA synthetase 1 (AARS1) raises questions about its metabolic functions in hepatocellular carcinoma. We examined phosphoglycerate dehydrogenase (PHGDH) as a potential lactylation substrate linking AARS1 to serine metabolism and tumour growth.</p><p><strong>Methods: </strong>Public expression data and patient tissues were studied alongside proteomic, lactylomic and targeted metabolomic profiles. Cellular and xenograft experiments used gene depletion, overexpression and reconstitution with wild-type or mutant proteins. Immunoprecipitation and activity measurements assessed PHGDH regulation. Survival was examined with Kaplan‒Meier estimates and Cox regression, while experimental groups were compared by t-tests or analysis of variance.</p><p><strong>Results: </strong>Of 140 paired specimens, 119 tumours (85%) had higher AARS1 mRNA than their non-tumour counterparts. Elevated AARS1 independently predicted poorer survival, and E2F4 depletion lowered AARS1 expression. AARS1 supported malignant phenotypes, lactate production and PHGDH lactylation. Mass spectrometry detected lactylation at PHGDH-K394. Relative to wild-type PHGDH, K394R showed less lactylation and supported lower lysate enzyme activity, serine, glycine and glutathione levels. The mutant also increased reactive oxygen species, provided weaker phenotypic rescue and supported less xenograft growth. Depleting AARS1 reduced enzyme activity and malignant phenotypes in the wild-type background; no further significant reduction was detected with K394R. β-Alanine inhibited xenograft growth, but PHGDH-K394 alone could not account for its effects.</p><p><strong>Conclusions: </strong>AARS1-associated PHGDH-K394 lactylation may connect serine metabolism and redox regulation to hepatocellular carcinoma progression. Establishing therapeutic relevance will require site-specific mechanistic experiments and additional preclinical validation.</p>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13770211/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402639","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Single-cell multiomics profiling reveals tumour microenvironment landscape and sex-specific immune-suppressive feature in male breast cancer.","authors":"Handong Sun, Ruilin Wang, Yanhao Wang, Meining Jiang, Cui-Cui Liu, Chuang Yang, Zhonglin Wang, Bing Sun, Jun Zhang, Mengtao Zhan, Zhou Fan, Yongsheng Li, Keda Yu","doi":"10.1002/ctm2.70894","DOIUrl":"https://doi.org/10.1002/ctm2.70894","url":null,"abstract":"<p><strong>Background: </strong>Male breast cancer (MBC) represents a small proportion of all breast cancer (BC) cases, yet it is characterized by a higher rate of lymph node metastasis and poorer prognosis compared to female breast cancer (FBC). However, limited research has been conducted on MBC primarily due to its rarity and the technological constraints.</p><p><strong>Methods: </strong>To address this, we performed single-nucleus RNA sequencing (snRNA-seq) on samples from 16 MBC patients (87 518 cells) and imaging mass cytometry (IMC) on samples from 42 patients (265 137 cells), enabling a comprehensive analysis of the MBC microenvironment at both single-cell transcriptome and protein levels.</p><p><strong>Results: </strong>At the autosomal level, the MBC tumor cells and their microenvironment exhibit distinct characteristics. We found that PDZ binding kinase (PBK) expression was elevated in MBC tumor cells and linked to proliferation-related programs, whereas SRY-Box transcription factor 4 (SOX4) expression was increased in endothelial cells and associated with endothelial-mesenchymal transition (EndMT) signatures and metastatic potential. Additionally, IMC analysis revealed notable differences in the spatial features of the tumor microenvironment between MBC and FBC. Regarding sex-chromosomal regulation, the lysine demethylase 5D (KDM5D) gene originating from the Y chromosome was associated with cGAS/STING protein abundance and reduced immune cell infiltration in MBC.</p><p><strong>Conclusion: </strong>In conclusion, both autosomal and sex-chromosomal regulation may collectively contribute to the modulation of microenvironmental differences between MBC and FBC. Whether KDM5D is functionally linked to cGAS/STING signaling requires further validation. Our findings provide insights into the unique microenvironment and clinical manifestations of MBC and generate hypotheses for future functional studies.</p><p><strong>Highlights: </strong>Multi-omics profiling reveals a distinct, relatively immune-cold microenvironment in male breast cancer. PBK expression is associated with proliferation programs in MBC epithelial cells. SOX4 expression in endothelial cells is linked to an EndMT-like phenotype. KDM5D-low status is associated with reduced cGAS/STING protein levels and immune infiltration.</p>","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402644","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Reducing the burden of diabetes through better care across the disease continuum.","authors":"Siqi Yang, Till Winfried Bärnighausen, Zhong Cao","doi":"10.1002/ctm2.70897","DOIUrl":"10.1002/ctm2.70897","url":null,"abstract":"","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13770212/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149402642","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Qian Li, Xiaowei Xie, Jie Chen, Yu Cao, Dingzhou Zhou
{"title":"Intranuclear localisation of KLF3-AS1 under the balance of histone acetylation and methylation in BMSCs ameliorates cerebral ischaemia‒reperfusion injury by preserving microglial mitochondrial function and inhibiting inflammatory polarisation","authors":"Qian Li, Xiaowei Xie, Jie Chen, Yu Cao, Dingzhou Zhou","doi":"10.1002/ctm2.70870","DOIUrl":"https://doi.org/10.1002/ctm2.70870","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Ischaemic stroke occurs when blood flow to the brain is obstructed. Rapid restoration of blood supply frequently induces cerebral ischaemia‒reperfusion injury (CIRI). Bone marrow mesenchymal stem cell (BMSC)-derived exosomes exhibit promising therapeutic potential for CIRI. In-depth exploration of their therapeutic mechanisms holds crucial significance for CIRI management.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The middle cerebral artery occlusion/reperfusion (MCAO) model was established in mice. An in vitro ischaemic stroke model was established by treating BV-2 cells with oxygen‒glucose deprivation/reoxygenation (OGD/R). Exosomes were isolated from BMSCs and intranasally administrated into mice or added into BV-2 cells. Neurological deficits, grasping and coordination function were evaluated. Cell viability, apoptosis, proliferation and migration were examined. The localisation of KLF3-AS1 was examined by combined staining of immunofluorescence and fluorescence in situ hybridisation. Intracellular Ca<sup>2+</sup> and adenosine triphosphate levels, mitochondrial reactive oxygen species and membrane potential were assessed.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>KLF3-AS1 enhanced BMSC viability, proliferation and migration, accompanied by epigenetic reprogramming at its promoter characterised by increased H3K27 acetylation (H3K27Ac) and decreased H3K27 trimethylation (H3K27Me3). BMSC-derived KLF3-AS1-enriched exosomes indicated therapeutic efficacy in both in vivo and in vitro models of cerebral ischaemia. In MCAO-induced mice, these exosomes alleviated neurological deficits and shifted microglial polarisation from pro-inflammatory M1-like to anti-inflammatory M2-like phenotypes. Similar effects were observed in OGD/R-treated BV-2 microglia, where KLF3-AS1-enriched exosomes attenuated oxidative stress and mitochondrial dysfunction while upregulating Silent Information Regulator 3 (SIRT3) expression. Mechanistically, KLF3-AS1 facilitated ETS Variant Transcription Factor 4 (ETV4) nuclear translocation to activate SIRT3 transcription in microglia, and inhibition of SIRT3 abolished the neuroprotective effects of exosomal KLF3-AS1.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>BMSC-derived exosomes delivering KLF3-AS1 ameliorates CIRI by preserving microglial mitochondrial function and inhibiting inflammatory polarisation, highlighting KLF3-AS1 as a critical epigenetic regulator and exosome-mediated therapeutic agent for CIRI through the ETV4/SIRT3 axis.</p>\u0000 </section>\u0000 \u0000","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70870","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149312794","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Jiaxing Wang, Chuan-Guo Guo, Lingyu Qi, Songyuan Hou, Boshen Lin, Tong Ye, Ye Zong, Shutian Zhang, Nan Zhang, Peng Li, Si Liu
{"title":"Epigenetic silencing of PDLIM4 promotes colorectal cancer by impairing BTF3 autophagic degradation and activating PI3K/Akt signalling","authors":"Jiaxing Wang, Chuan-Guo Guo, Lingyu Qi, Songyuan Hou, Boshen Lin, Tong Ye, Ye Zong, Shutian Zhang, Nan Zhang, Peng Li, Si Liu","doi":"10.1002/ctm2.70882","DOIUrl":"10.1002/ctm2.70882","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Epigenetic silencing of tumour suppressor genes is a pivotal early event in colorectal cancer (CRC) pathogenesis. PDZ and LIM Domain 4 (PDLIM4) is a member of the PDZ-LIM family with context-dependent roles in tumour progression across different malignancies. However, its specific role and epigenetic regulation in colorectal cancer (CRC) remain elusive.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We integrated multi-omics datasets and clinical cohorts to evaluate PDLIM4 expression and promoter methylation. Stool DNA was analyzed to assess the feasibility of non-invasive detection of PDLIM4 promoter methylation. PDLIM4 knockout and overexpression cell lines were constructed to perform functional assays including proliferation, apoptosis, and stemness. In vivo experiments were validated utilizing xenograft mice or an azoxymethane (AOM)/ dextran sulphate sodium salt (DSS) CRC mouse model with intestinal epithelial cell-specific overexpression of PDLIM4. Mechanistic investigations were conducted using coimmunoprecipitation coupled with mass spectrometry, RNA sequencing, ChIP-qPCR and pharmacological rescue experiments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We identified a progressive loss of PDLIM4 protein along the normal-adenoma-carcinoma sequence, driven by DNMT3A-mediated promoter hypermethylation, and lower PDLIM4 expression was associated with adverse patient prognosis. PDLIM4 methylation was also significantly increased in stool DNA from CRC patients compared with healthy controls. Mechanistically, genetic ablation of PDLIM4 significantly blunted the therapeutic efficacy of the DNA demethylating agent 5-Azacytidine against CRC. Functionally, PDLIM4 restoration suppressed CRC cell proliferation and stemness while enhancing apoptosis in vitro, and reduced tumour growth in both AOM/DSS and xenograft models in vivo. At the molecular level, PDLIM4 interacted with BTF3 and promoted its autophagic-lysosomal degradation, thereby limiting PI3K/Akt signalling, with NTRK2 identified as a potential transcriptional target linking BTF3 to PI3K/Akt activation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>DNMT3A-mediated silencing of PDLIM4 is an early epigenetic event that facilitates CRC progression. PDLIM4 suppresses tumour growth by promoting BTF3 degradation, thereby restricting PI3K/Akt signalling. Thus, PDLIM4 methylation may have potential as a biomarker for early CRC detection.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Key points</h3>\u0000 ","PeriodicalId":10189,"journal":{"name":"Clinical and Translational Medicine","volume":"16 11","pages":""},"PeriodicalIF":7.9,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/ctm2.70882","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149295103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}